Loading clinical trials...
Loading clinical trials...
A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.
Conditions
Interventions
HLX07
Acetaminophen
+3 more
Locations
2
United States
Henlix, Inc.
Fremont, California, United States
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan
Start Date
September 1, 2016
Primary Completion Date
June 28, 2019
Completion Date
June 28, 2019
Last Updated
July 30, 2019
NCT07331155
NCT07403370
NCT06815575
NCT05770102
NCT06883539
NCT07474558
Lead Sponsor
Henlix, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions